Cargando…

Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report

H3K27M-mutant diffuse midline glioma (H3K27M-mt DMG) was a novel entity, which was defined by K27M mutations in H3F3A or HIST1H3B/C in the 2016 WHO updated fourth edition of the central nervous system (CNS) tumor classification. There is an urgent need for effective therapeutic strategies. Anlotinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiang, Niu, Wenhao, Pan, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609840/
https://www.ncbi.nlm.nih.gov/pubmed/34812950
http://dx.doi.org/10.1007/s00701-021-05061-1

Ejemplares similares